Covid 19 Research using Clinical Trials (Home Page)
Milk of magnesiaWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
|
Name (Synonyms) |
Correlation |
drug299 | BMS-986256 Wiki | 1.00 |
drug341 | Best supportive care" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy Wiki | 1.00 |
drug1268 | Itolizumab IV infusion Wiki | 1.00 |
Correlated MeSH Terms (4)
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
The purpose of this study is to assess the way the body absorbs, distributes, breaks down and
eliminates radioactive BMS-986856 in healthy males.
NCT04269356 Healthy Participants Drug: BMS-986256 Drug: Milk of magnesia
Primary Outcomes
Measure: Maximum observed plasma concentration (Cmax) of [14C] BMS-986256 Time: Up to 49 days
Measure: Time to attain maximum observed plasma concentration (Tmax) of [14C] BMS-986256 Time: Up to 49 days
Measure: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC (0-T)) of [14C] BMS-986256 Time: Up to 49 days
Secondary Outcomes
Measure: Incidence of Adverse Events (AEs) Time: Up to 49 days
Measure: Incidence of Serious Adverse Events (SAEs) Time: Up to 49 days
Measure: Incidence of clinically significant changes in clinical laboratory results: Hematology tests Time: Up to 49 days
Measure: Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests Time: Up to 49 days
Measure: Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests Time: Up to 49 days
Measure: Incidence of clinically significant changes in vital signs: Blood pressure Time: Up to 49 days
Measure: Incidence of clinically significant changes in vital signs: Heart rate Time: Up to 49 days
Measure: Incidence of clinically significant changes in vital signs: Respiratory rate Time: Up to 49 days
Measure: Incidence of clinically significant changes in vital signs: Body temperature Time: Up to 49 days
Measure: Incidence of clinically significant changes in electrocardiogram (ECG) parameters Time: Up to 49 days
Measure: Incidence of clinically significant changes in physical examination findings Time: Up to 49 days
No related HPO nodes (Using clinical trials)